A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
A study for patients with incurable cancers using study drug CPI-444
Sponsor: Corvus Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ6651
U.S. Govt. ID: NCT02655822
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is for patients with incurable cancers such as, metastatic non-small cell lung cancer, melanoma, renal cell carcinoma, triple negative breast cancer, colorectal cancer, head and neck cancer, castrate resistant prostate cancer and bladder cancer. The purpose of this study is find out whether an investigational (experimental) drug called CPI-444 can be used, either on its own, or in combination with another investigational drug called atezolizumab (also known as MPDL3280A) on patients and the specific type of cancer they have. We want to find out the best dose of CPI-444, both on its own and in combination with atezolizumab and what effects, good and/or bad, either CPI-444 on its own or in combination with atezolizumab has on patients with incurable cancers.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with any of the cancers mentioned above? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator